Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2025)

Roivant Sciences (ROIV) reported Income from Non-Controlling Interests of -$47.8 million for Q4 2025, up 6.81% on a YoY basis from -$44.8 million in Q4 2024, and up 8.97% quarter-over-quarter from -$52.5 million in Q3 2025.

Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends

Roivant Sciences has reported Income from Non-Controlling Interests for 6 years, with the latest figure at -$47.8 million in Q4 2025.

  • For the quarter ending Q4 2025, Income from Non-Controlling Interests rose 6.81% year-over-year to -$47.8 million; the trailing twelve-month figure through Dec 2025 stood at -$202.2 million (down 24.52% YoY), and the FY2026 full-year result was -$98.1 million, up 46.88% from the prior year.
  • Income from Non-Controlling Interests for Q4 2025 stood at -$47.8 million, up from -$52.5 million in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was -$17.2 million in Q3 2021, with the low at -$52.5 million in Q3 2025.
  • Historically, Income from Non-Controlling Interests has averaged -$34.2 million across 5 years, with a median of -$32.9 million in 2022.
  • Annual changes were most pronounced in 2021 — Income from Non-Controlling Interests sank 299.13% — and 2023, when it rose 28.47%.
  • Roivant Sciences' Income from Non-Controlling Interests stood at -$21.5 million in 2021, then tumbled by 52.59% to -$32.9 million in 2022, then climbed by 28.47% to -$23.5 million in 2023, then slumped by 118.15% to -$51.3 million in 2024, then climbed by 6.81% to -$47.8 million in 2025.
  • The last three Income from Non-Controlling Interests figures came in at -$47.8 million (Q4 2025), -$52.5 million (Q3 2025), and -$50.6 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.75 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Roivant Sciences 21.82 Bn 22.59 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -47.81 Mn
Sep 30, 2025 -52.52 Mn
Jun 30, 2025 -50.56 Mn
Dec 31, 2024 -51.31 Mn
Sep 30, 2024 -49.74 Mn
Jun 30, 2024 -37.81 Mn
Dec 31, 2023 -23.52 Mn
Sep 30, 2023 -26.79 Mn
Jun 30, 2023 -36.03 Mn
Dec 31, 2022 -32.88 Mn
Sep 30, 2022 -24.33 Mn
Jun 30, 2022 -21.98 Mn
Dec 31, 2021 -21.55 Mn
Sep 30, 2021 -17.16 Mn
Jun 30, 2021 -18.90 Mn
Dec 31, 2020 -14.57 Mn
Sep 30, 2020 -18.10 Mn
Jun 30, 2020 -4.73 Mn